Bernhardt G. Zeiher, a director at Entrada Therapeutics (NASDAQ:TRDA), purchased 5,000 shares of common stock on May 20, 2026, for a total of $29,316.
The shares were acquired at prices ranging from $5.86 to $6.00. The stock currently trades at $6.31, down 41% year-to-date. Bond.az analysis suggests the stock is undervalued relative to its Fair Value.
The purchase was made indirectly through a trust. Following the transaction, Zeiher's indirect ownership stands at 5,000 shares.
In other news, Entrada is set to announce topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44. The company will host a webcast and conference call to discuss results.
